121 related articles for article (PubMed ID: 36740223)
1. Determination of TMPRSS2-ERG, SPOP, FOXA1, and IDH1 prostate cancer molecular subtypes in Colombian patients and their possible implications for prognosis.
Montero-Ovalle W; Sanabria-Salas MC; Mesa-López de Mesa J; Varela-Ramírez R; Segura-Moreno YY; Sánchez-Villalobos SA; Nuñez-Lemus M; Serrano ML
Cell Biol Int; 2023 May; 47(5):1017-1030. PubMed ID: 36740223
[TBL] [Abstract][Full Text] [Related]
2. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
Hernández-Llodrà S; Segalés L; Safont A; Juanpere N; Lorenzo M; Fumadó L; Rodríguez-Vida A; Cecchini L; Bellmunt J; Lloreta-Trull J
Prostate; 2019 Jul; 79(10):1156-1165. PubMed ID: 31090082
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of gene expression in localized and metastatic prostate cancer exemplified by FABP5.
Nitschke K; Erben P; Waldbillig F; Abdelhadi A; Weis CA; Gottschalt M; Wahby S; Nuhn P; Boutros M; Michel MS; von Hardenberg J; Worst TS
World J Urol; 2020 Mar; 38(3):637-645. PubMed ID: 30701334
[TBL] [Abstract][Full Text] [Related]
4. Determination of ERG(+), EZH2, NKX3.1, and SPINK-1 subtypes to evaluate their association with clonal origin and disease progression in multifocal prostate cancer.
Segura-Moreno YY; Sanabria-Salas MC; Mesa-López De Mesa JA; Varela-Ramirez R; Acosta-Vega NL; Serrano ML
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1728. PubMed ID: 36199157
[TBL] [Abstract][Full Text] [Related]
5. Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer.
Barros-Silva JD; Ribeiro FR; Rodrigues A; Cruz R; Martins AT; Jerónimo C; Henrique R; Teixeira MR
Genes Chromosomes Cancer; 2011 Aug; 50(8):662-71. PubMed ID: 21584900
[TBL] [Abstract][Full Text] [Related]
6. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.
Darnel AD; Lafargue CJ; Vollmer RT; Corcos J; Bismar TA
Cancer Biol Ther; 2009 Jan; 8(2):125-30. PubMed ID: 19029822
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status.
Luedeke M; Rinckleb AE; FitzGerald LM; Geybels MS; Schleutker J; Eeles RA; Teixeira MR; Cannon-Albright L; Ostrander EA; Weikert S; Herkommer K; Wahlfors T; Visakorpi T; Leinonen KA; Tammela TLJ; Cooper CS; Kote-Jarai Z; Edwards S; Goh CL; McCarthy F; Parker C; Flohr P; Paulo P; Jerónimo C; Henrique R; Krause H; Wach S; Lieb V; Rau TT; Vogel W; Kuefer R; Hofer MD; Perner S; Rubin MA; Agarwal AM; Easton DF; Al Olama AA; Benlloch S; ; Hoegel J; Stanford JL; Maier C
Hum Mol Genet; 2016 Dec; 25(24):5490-5499. PubMed ID: 27798103
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
[TBL] [Abstract][Full Text] [Related]
9. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.
Magi-Galluzzi C; Tsusuki T; Elson P; Simmerman K; LaFargue C; Esgueva R; Klein E; Rubin MA; Zhou M
Prostate; 2011 Apr; 71(5):489-97. PubMed ID: 20878952
[TBL] [Abstract][Full Text] [Related]
10. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.
Miyagi Y; Sasaki T; Fujinami K; Sano J; Senga Y; Miura T; Kameda Y; Sakuma Y; Nakamura Y; Harada M; Tsuchiya E
Mod Pathol; 2010 Nov; 23(11):1492-8. PubMed ID: 20693979
[TBL] [Abstract][Full Text] [Related]
11. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.
Qu X; Randhawa G; Friedman C; O'Hara-Larrivee S; Kroeger K; Dumpit R; True L; Vakar-Lopez F; Porter C; Vessella R; Nelson P; Fang M
Cancer Genet; 2013; 206(1-2):1-11. PubMed ID: 23352841
[TBL] [Abstract][Full Text] [Related]
12. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues.
Tu JJ; Rohan S; Kao J; Kitabayashi N; Mathew S; Chen YT
Mod Pathol; 2007 Sep; 20(9):921-8. PubMed ID: 17632455
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
Pernar CH; Ebot EM; Pettersson A; Graff RE; Giunchi F; Ahearn TU; Gonzalez-Feliciano AG; Markt SC; Wilson KM; Stopsack KH; Gazeeva E; Lis RT; Parmigiani G; Rimm EB; Finn SP; Giovannucci EL; Fiorentino M; Mucci LA
Eur Urol; 2019 Jul; 76(1):33-40. PubMed ID: 30301696
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and clinical application of
Kong DP; Chen R; Zhang CL; Zhang W; Xiao GA; Wang FB; Ta N; Gao X; Sun YH
Asian J Androl; 2020; 22(2):200-207. PubMed ID: 31210145
[TBL] [Abstract][Full Text] [Related]
15. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status.
Mancarella C; Casanova-Salas I; Calatrava A; García-Flores M; Garofalo C; Grilli A; Rubio-Briones J; Scotlandi K; López-Guerrero JA
BMC Cancer; 2017 May; 17(1):367. PubMed ID: 28545426
[TBL] [Abstract][Full Text] [Related]
17. Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status.
Geybels MS; McCloskey KD; Mills IG; Stanford JL
Prostate; 2017 Feb; 77(3):282-290. PubMed ID: 27753122
[TBL] [Abstract][Full Text] [Related]
18. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
[TBL] [Abstract][Full Text] [Related]
19. SPOP mutations in prostate cancer across demographically diverse patient cohorts.
Blattner M; Lee DJ; O'Reilly C; Park K; MacDonald TY; Khani F; Turner KR; Chiu YL; Wild PJ; Dolgalev I; Heguy A; Sboner A; Ramazangolu S; Hieronymus H; Sawyers C; Tewari AK; Moch H; Yoon GS; Known YC; Andrén O; Fall K; Demichelis F; Mosquera JM; Robinson BD; Barbieri CE; Rubin MA
Neoplasia; 2014 Jan; 16(1):14-20. PubMed ID: 24563616
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
